Finance

Lists
Why is VYGR up 3.49%?
Dive Deeper
VYGR:NASDAQ
Voyager Therapeutics Inc
$1.78
+3.49%
(+0.060) 1D
$1.79
+0.56% (+0.0100)
After hours
Closed: Nov 2, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VYGR...
Open
$1.74
High
$1.80
Low
$1.71
Mkt. cap
109.68M
Avg. vol.
899.51K
Volume
0.00
52-wk high
$5.48
52-wk low
$1.68
EPS
-$1.81
Beta
1.29
Shares outstanding
61.62M
No. of employees
141
Open
$1.74
High
$1.80
Low
$1.71
Mkt. cap
109.68M
Avg. vol.
899.51K
Volume
0.00
52-wk high
$5.48
52-wk low
$1.68
EPS
-$1.81
Beta
1.29
Shares outstanding
61.62M
No. of employees
141
News stories
From web sources and news partners
About Voyager Therapeutics Inc
CEO-
Employees141
Founded2013
HeadquartersLexington, Massachusetts, United States
SectorBiotechnology
Websitevoyagertherapeutics.com
Analyst ratings
Based on 5 analysts giving stock ratings to VYGR in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for VYGR in the last 3 months.
Highest
Current $1.78
$25.00 (+1,304.49%)
Average
$13.75 (+672.47%)
Lowest
$8.00 (+349.44%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$25.00
+1,304.5%
10/28/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$12.00
+574.2%
10/23/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$10.00
+461.8%
10/02/2026
Yun Zhong
Wedbush
Buy
Maintained
$8.00
+349.4%
08/07/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
08/06/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$22.00
+1,136%
06/02/2026
Unknown Analyst
Oppenheimer
Buy
Maintained
$18.00
+911.2%
05/08/2026
Samantha Semenkow
Citi
Buy
Reiterated
$11.00
+518%
03/23/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/17/2026
Next call in 11 days
Fri, Nov 13, 4:00 PM
Fiscal period
Q3 2026
- / -$0.42
Revenue / Est. (USD)
- / 6.35M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.36M
15.34M
2.59M
3.16M
Cost of goods sold
35.87M
33.55M
24.60M
22.04M
Cost of revenue
35.87M
33.55M
24.60M
22.04M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.09M
8.22M
8.26M
7.52M
Operating expense
8.09M
8.22M
8.26M
7.52M
Total operating expenses
43.96M
41.77M
32.86M
29.56M
Operating income
-30.59M
-26.43M
-30.27M
-26.39M
Other non operating income
400.00K
404.00K
435.00K
411.00K
EBT including unusual items
-27.81M
-27.42M
-27.92M
-24.45M
EBT excluding unusual items
-27.81M
-23.92M
-27.92M
-24.45M
Income tax expense
83.00K
9.00K
14.00K
20.00K
Effective tax rate
-0.30%
-0.03%
-0.05%
-0.08%
Other operating expenses
-
-
-
-
Net income
-27.89M
-27.43M
-27.94M
-24.47M
Net profit margin
-208.69%
-178.83%
-1,077.40%
-773.24%
Earnings per share
-0.47
-0.47
-0.47
-0.40
Interest and investment income
2.38M
2.11M
1.91M
1.53M
Interest expense
-
-
-
-
Net interest expenses
2.38M
2.11M
1.91M
1.53M
Depreciation and amortization charges
-
-
-
-
EBITDA
-29.66M
-25.38M
-29.34M
-25.48M
Gain or loss from assets sale
-
62.00K
-
105.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps